Yasmin and its sister drug Yaz were introduced in the market over ten years ago. The drugs, made by Bayer, achieved $1.47 billion in sales during 2010 alone. The drug sold well, but proved to have devastating side effects that sometimes proved fatal.
Litigation commenced many years ago and many cases have settled. However, Bayer…
Bayer released a series of Saturday-morning-style cartoons for sales representative training purposes, which they seemingly hoped would motivate their sales reps to continue marketing their birth control drugs, including Yaz. One particular cartoon is entitled “IndiYaz A Jones and the Temple of Estradiol.” Estradiol is a hormone that is contained in the Yaz contraceptive, which…
On July 11, 2012, The Madison Record reported that the special master appointed to oversee settlement negotiations for the federal MDL case, Stephen Saltzburg, estimates that negotiations could be concluded within a year. To date, it is reported that, almost 2,000 lawsuits have settled. As we previously advised, Bayer reports that it has set aside…
According to a recent Bloomberg article, Bayer reports that the settlements in the Yaz and Yasmin lawsuits have reached $402.6 million. As we previously reported, Bayer’s defense counsel is currently conducting and scheduling meetings with law firms nationwide to discuss possible settlement of cases. To date, almost 2,000 cases have settled. As we also…
As previously reported, in December 2011, the Federal Drug and Administration (FDA) ruled that the label warning on Bayer Yaz and Yasmin regarding the increased risk of blood clots was inadequate. The decision followed a nine-hour hearing during which the FDA’s Advisory Committee listened to testimony and, according to the FDA website, “discuss[ed] the benefits…
In June 2012, a study, published in the New England Journal of Medicine, reported that that birth control products containing combined estrogen-progestin, such as Yaz or Yasmin, may double a woman’s risk of stroke and heart attack compared to other hormonal contraceptives. The study, based on data compiled over 15 years from more than 1.5…
Following the December 2011, ruling by the Federal Drug and Administration (FDA) that the label warnings on Yaz and Yasmin failed to adequately warn against the increased risk of blood clots, Bayer began contacting Plaintiffs across the country to settle their Yaz lawsuit. In April 2012, a Bloomberg article reported that Bayer had already settled…
Recently, the Plaintiffs’ Steering Committee in the Yaz and Yasmin litigation opposed a motion to exclude the opinions of former Food and Drug Administration (FDA) commissioner, David Kessler, concerning possible conflicts of interest. The Plaintiffs’ attorneys have asked Judge Herndon, who is overseeing the federal Yaz and Yasmin cases, to allow in evidence showing that…
On January 6, 2012, Judge Moss, who is overseeing the state Yaz cases in Philadelphia, followed in Judge Herndon’s footsteps and ordered the parties into mediation. Like Judge Herndon, who is overseeing the federal Yaz cases, Judge Moss also appointed Professor Stephen Saltzburg of George Washington School of Law as Special Master, for the purposes…
The first federal Yaz trial is not moving forward as planned. While the highly anticipated trial was originally scheduled to begin the second week of January 2012, Judge Herndon, who is overseeing the federal Yaz cases in the Southern District of Illinois, has now ordered both sides to mediation.
On December 31, 2011, Judge Herndon…
